Selective C-reactive protein apheresis in acute myocardial infarction: rationale and design of a prospective international randomized controlled trial
The goal is to demonstrate the safety and efficacy of CRP apheresis in AMI in reducing the combined primary clinical endpoint of cardiovascular mortality or rehospitalization for heart failure.
Authors
- Jan Torzewski (ORCID: https://orcid.org/0000-0003-4959-7293)
- Gregg W. Stone (ORCID: https://orcid.org/0000-0002-3416-8210)
- Ahmed Sheriff (ORCID: https://orcid.org/0000-0001-5074-1198)
- Benjamin Mayer (ORCID: https://orcid.org/0000-0003-1042-9006)
- Stephan Mattecka (ORCID: https://orcid.org/0009-0000-1149-4075)
Institutions
- Universität Ulm (DE)
- Kempten University of Applied Sciences (DE)
- Zimmer Biomet (Germany) (DE)
- Charité - Universitätsmedizin Berlin (DE)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Coronary Artery Disease
- Published
- 2025-03-30
- DOI
- https://doi.org/10.1097/mca.0000000000001521
- Citations
- 1
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.40